Healthcare >> Analyst Interviews >> October 19, 2009

Outlook For Large-cap Biotechnology – Maged Shenouda – Ubs Investment Research

MAGED SHENOUDA is an Executive Director in the health care group of UBS Investment Research, specializing in coverage of large-cap biotechnology companies. An Analyst since 1999, he joined UBS in 2004 from J.P. Morgan, where he had served as a Biotechnology Analyst since 2000. Mr. Shenouda earlier worked as biotech and European Pharmaceuticals Analyst at Bear, Stearns & Co., and as an Associate Pharmaceuticals Analyst at Solomon Smith Barney. Prior to that, he was a Management Consultant with Price Waterhouse, focusing on the pharmaceutical industry, and he served as a Pharmaceutical Sales Representative for Abbott Laboratories. Mr. Shenouda holds an MBA in marketing from Rutgers University and a B.S. in pharmacy from St. John's University's College of Pharmacy. He is a registered pharmacist in New Jersey and California. Profile
TWST: What do you cover within the biotech sector?

Mr. Shenouda: I cover U.S. large-cap biotechnology as well as some mid- and small-cap names.

TWST: How do you define biotech?

Mr. Shenouda: The